Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Lightlake Therapeutics will conduct Phase II trials on opioid antagonist-based nasal spray treatment for Bulimia Nervosa at King's College London.
Subscribe to our email newsletter
Bulimia Nervosa is a binge eating disorder.
Currently, Lightlake is focused on providing a safe, effective and simple treatment for patients with Bulimia Nervosa as well as those who are obese or overweight as a result of Binge Eating Disorder.
The company also holds various patents that are believed to help in expansion of its product portfolio to address patients with addictions to opioid painkillers, methadone, cocaine and amphetamine.